Investigational drug · Phase 3
BMN 333
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Achondroplasia.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BMN 333"
First trial start
2026
Apr 20, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BMN 333", any sponsor or status.
Conditions studied
As listed on its trial records.
- Achondroplasia
Approved drugs for the same conditions: Achondroplasia · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "BMN 333" as an intervention, largest first.
- Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaPivotal-lookingRecruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT07441876 · 160 participants (planned) · Start Apr 20, 2026 · Primary completion Jun 2029
Drug: BMN 333; Vosoritide Injection [Voxzogo] · For: Achondroplasia
Sites: Oakland, California; Wilmington, Delaware; Chicago, Illinois · 28 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Achondroplasia
- Modified recombinant human C-type natriuretic peptideBMN 111Phase 32 trials
BioMarin · Achondroplasia
- KK8398Phase 31 trial
Kyowa Kirin Co., Ltd. · Achondroplasia
- DabogratinibTYRA-300Phase 24 trials
Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia
- ABSK061Phase 22 trials
Abbisko Therapeutics Co, Ltd · HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer
- Combination of NavepegritidePhase 21 trial
Ascendis Pharma Growth Disorders A/S · Achondroplasia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BioMarin.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.